‘Opportunistic’ Salpingectomy at the Time of Hysterectomy: Risks vs Benefits
BACKGROUND AND PURPOSE:
To prevent ovarian cancer, ACOG guidance recommends a discussion with patients who are undergoing hysterectomy with ovarian conservation to consider opportunistic salpingectomy
Salpingectomy during laparoscopic and open hysterectomy adds minimal time with no additional complications
Salpingectomy during vaginal hysterectomy requires additional skills and may be associated with a modest increase in complications
Cadish et al. (AJOG, 2017), using decision analysis and cost-effectiveness models, sought to compare risk/benefit between women undergoing vaginal hysterectomy alone vs vaginal hysterectomy with planned salpingectomy
Researchers created a decision analysis model
Effectiveness outcomes were ovarian cancer incidence and mortality as well as major surgical complications
Modeled complications included transfusion, conversion to laparotomy or laparoscopy, abscess/hematoma requiring intervention, ileus, readmission, and reoperation within 30 days
Costs were gathered from published literature and Medicare reimbursement data
Complication rates were determined from published literature and National Surgical Quality Improvement Program database
More major complications were associated when salpingectomy was added to vaginal hysterectomy (7.95% vs 7.68%)
Complications included transfusion, conversion to laparotomy or laparoscopy, abscess/hematoma requiring intervention, ileus, readmission, and reoperation within 30 days
However, including salpingectomy during vaginal hysterectomy was the dominant cost-effective strategy because
It is a less expensive strategy than not performing salpingectomy ($7350.62 vs $8113.45)
Switching from a policy of vaginal hysterectomy alone to a policy of routine planned salpingectomy prevents a diagnosis of ovarian cancer in 1 of every 225 women undergoing surgery
1 ovarian cancer death would be prevented among every 450 women having surgery
Sensitivity analysis demonstrated the driving force behind increased costs was the operating room costs for increased risk of future benign adnexal surgeries
The finding of planned salpingectomy as the dominant strategy persisted even without taking in to account the cost of potential cancer treatments
Salpingectomy during vaginal hysterectomy was cost-effective and a superior strategy than hysterectomy alone
Efforts should be made to strengthen vaginal hysterectomy training and techniques related to salpingectomy
Please login to access ObGFirst and the T2 US Atlas
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan